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ABSTRACT
We here report 25 patients with nonmalignant disorders, ie, severe aplastic anemia (SAA, n  12) or inborn
errors of metabolism (IEM, n  13), who underwent allogeneic hematopoietic stem cell transplantation
(HSCT) from unrelated high-resolution typed HLA-A, -B, and -DR1 identical donors. One patient had an
HLA-B subtype-mismatched donor. Conditioning for SAA mainly consisted of cyclophosphamide and total
body irradiation, and that for IEM consisted of busulfan and cyclophosphamide. All patients received antithy-
mocyte globulin during conditioning. After HSCT, they were given cyclosporine combined with methotrexate
for immunosuppression. Two patients rejected their grafts: 1 died of pneumonia, and the other was success-
fully regrafted. The cumulative incidence of acute graft-versus-host disease grades II to IV was 24%, whereas
chronic graft-versus-host disease occurred in 21%. The 5-year survival rates were 83% in the SAA group and
85% in those with IEM. We conclude that HSCT with HLA-A, -B, and -DR1 genomically matched unrelated
donors in combination with antithymocyte globulin in the conditioning regimen gives encouraging results in
patients with SAA or IEM.
© 2004 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
During the last 3 decades, hematopoietic stem cell
ransplantation (HSCT) has emerged as a curative
herapeutic approach in an increasing number of le-
hal disorders affecting the hematopoietic system
1-5]. HSCT with HLA-identical sibling donors is
lso the treatment of choice for some rare congenital
etabolic and nonmalignant lymphohematopoietic
isorders [3-5]. However, because only one third of
he patients have a genetically HLA-identical sibling,
he use of HLA-matched unrelated donors (MUD)
as increased over the last 10 years [6-11]. Patients
ith severe aplastic anemia (SAA) are treated with
mmunosuppressive therapy by using antithymocyte
lobulin (ATG) and cyclosporine (CsA) if an HLA-
dentical sibling donor is not available. However, if the
atients do not respond to this treatment, then they
ay be given HSCT by using a MUD [5,9]. Patients r
B & M Tndergoing HSCT with MUD for SAA are therefore
selected high-risk group who have not been success-
ully treated. In patients with certain inborn errors of
etabolism (IEM), HSCT is often the only possible
ure [3,4]. Consequently, HSCT from an unrelated
onor is also considered desirable in the absence of a
ell-matched related donor [12]. We report our ex-
erience with MUD-HSCT in 25 patients with life-
hreatening nonmalignant disorders.
ATIENTS AND METHODS
atients
Between 1993 and 2003, 25 patients with nonma-
ignant disorders underwent HSCT with HLA-A–,
LA-B–, and HLA-DR–compatible MUDs, except
, who had an HLA-B subtype-mismatched donor. All
eceived ATG during conditioning. Eleven patients
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8ad SAA, and 1 had Fanconi anemia. Thirteen pa-
ients had IEM: mucopolysaccharidosis (MPS, n  4),
ncluding 3 with Hurler disease (MPS type 1) and 1
ith Sanﬁlippo syndrome (MPS type III); severe com-
ined immune deﬁciency (SCID; n  1) and hemo-
hagocytic lymphohistiocytosis (HLH, n  4); and
eukodystrophy (n  4), including 2 patients with
etachromatic leukodystrophy and 2 with adrenoleu-
odystrophy (ALD). At the time of transplantation,
heir ages ranged from 0 to 39 years, with a median
ge of 6 years. Fourteen were male. The characteris-
ics of the patients with SAA and of those with IEM
re shown in Tables 1 and 2, respectively.
onors
The donors were procured from various national
onor registries. All patients were recently retrospec-
ively retyped with polymerase chain reaction/
equence-speciﬁc priming high-resolution typing for
LA class I and II antigens [13,14]. All donors were
ully HLA-A, -B, and -DR1 matched, except 1 (the
onor for patient 644), who had an HLA-B subtype
ismatch. Twenty patients received bone marrow.
ive patients were given peripheral blood progenitor
ells from donors treated with granulocyte colony-
timulating factor (G-CSF) [15]. The mean nucleated
ell dose, corrected for donor peripheral blood leuko-
ytes, was 3.6  108/kg (range, 0.6-59.3  108/kg).
ifteen of the donors were male, and 10 were female.
heir ages ranged from 21 to 47 years, with a median
ge of 40 years.
onditioning
One patient with SAA was conditioned with cy-
lophosphamide (Cy) 50 mg/kg for 4 consecutive
ays, followed by 2 Gy of total lymph node irradiation
TLI) on 3 consecutive days. The subsequent patients
ith SAA received conditioning that consisted of Cy
0 mg/kg/d for 2 consecutive days in combination
ith fractionated total body irradiation (TBI)—3 Gy
or 2 days (n 6), a single dose of 10 Gy of TBI (9 Gy
o lungs; n  3), a single dose of 7.5 Gy of TBI (dose
ate, 26 cGy/min); 2 Gy of TLI for 4 days (n 1); and
usulfan 4 mg/kg/d for 4 days (n 1) [16]. Five of the
atients given fractionated TBI were also given ﬂu-
arabine 30 mg/m2/d for 3 days. The patient with
anconi anemia was conditioned with ﬂudarabine 30
g/m2/d for 5 days followed by Cy 10 mg/kg/d for
days.
Twelve patients with IEM were given busulfan 4
g/kg/d for 4 days followed by 4 days of Cy 2 g/m2/d
17]. One patient was given Cy 60 mg/d for 2 days and
ractionated TBI 3 Gy for 4 days. Four patients with
LH were also given etoposide 30 mg/kg. To prevent
emorrhagic cystitis caused by Cy, intravenous (IV)
uids 3 L/m2/d were given, together with mesna 6 I
78imes in 24 hours at 20% of the Cy dose (Tables 1 and
). All patients received rabbit ATG (Thymoglobulin;
MTIX, Sangstat-Lyon, France); the total dose
anged between 2.9 and 12.8 mg/kg, with a median of
.0 mg/kg [18].
rophylaxis and Treatment of Graft-versus-Host
isease
Eighteen patients received 4 doses of methotrex-
te (MTX) combined with CsA [19]. MTX was given
n a dose of 15 mg/m2 IV on day1 and 10 mg/m2 on
ays 3, 6, and 11, according to the Seattle protocol
19]. CsA was started on the day before transplanta-
ion with an IV dose of 2.5 to 5 mg/kg  2, followed
y 1.5 to 3.5 mg/kg  2 from the day of transplanta-
ion. The higher dose was given to smaller children.
n day 1, or as soon as the patient could take CsA
rally, 6.25 to 10 mg/kg  2 was given. This regimen
as maintained for 12 to 24 months after HSCT, and
he dose was adjusted according to renal function and
erum CsA concentrations. During the ﬁrst month, we
imed at a CsA trough concentration in whole blood
f 200 to 300 ng/mL. Four patients received CsA as
escribed previously and received mycophenolate
ofetil 15 mg/kg twice daily from day 0 to day 28
fter the stem cell transplantation instead of MTX
20]. Three patients (patients 954, 955, and 971) re-
eived tacrolimus 4 mg  2 from day 3 and siroli-
us 6 mg  2. On day 2, the dose of sirolimus was
ecreased to 2 mg  2. Thereafter, both the sirolimus
nd tacrolimus dosages were adjusted according to
lasma levels. Tacrolimus was given for 18 months in
he absence of graft-versus-host disease (GVHD), and
he dose of sirolimus was tapered after 3 months. At
he ﬁrst sign of grade I acute GVHD, we gave pred-
isolone 2 mg/kg/d to adults and 2 to 3 mg/kg/d to
hildren for 1 week [16]. Thereafter, the dose was
educed, depending on the response. Some patients
ith severe GVHD also received methylprednisolone
V or psoralen and UV light. Chronic GVHD was
lassiﬁed as limited or extensive [21] and was treated
ith prednisolone and CsA [22].
upportive Care
All patients were kept in reverse isolation until the
bsolute neutrophil count (ANC) reached 0.2 109/L
or 2 consecutive days [16]. Four patients with SAA
nd 8 with IEM were given G-CSF 0.3 mg/d IV from
ay 10 after HSCT until ANC reached 0.5 
09/L for 2 consecutive days. Details regarding sup-
ortive care have been reported elsewhere [15-18].
tatistics
Analysis was performed as of May 3, 2004. The
ctuarial probabilities of survival, acute GVHD grades
I to IV, and chronic GVHD were calculated by the
Table 1. Severe Aplastic Anemia: Patient and Donor Characteristics
Patient No. Diagnosis
Recipient
Age (y)/Sex
Donor
Age (y)/Sex
Cell Dose
(MNC108/kg) Conditioning
CMV Serology
G-CSF
5g/kg/d
Acute
GVHD Grade
Chronic
GVHD Grade OutcomeDonor Recipient
249 SAA 39/F 42/F 2.5 Bu  Cy   N I 0 A & W
418 SAA 1/F 40/M 4.6 10 Gy TBI  Cy   N I 0 A & W
441 SAA 12/F 36/F 3.7 Cy  TLI   Y II 0 Dead, Evans
syndrome
485 SAA 19/F 44/M 1.3 7.5 Gy TBI  Cy
 TLI
  Y 0 Mild A & W
520 SAA 30/M 41/F 1.5 10 Gy TB1  Cy   Y I Mild Dead, ARDS
731 SAA 9/F 42/M 4.3 fTBI  Cy   Y I 0 A & W
887 SAA 37/M 39/M 0.6 fTBI  Cy  Flu   N 0 0 A & W
909 SAA 6/F 21/M 8.3 fTBI  Cy  Flu   N I 0 A & W
919 SAA 39/M 43/M 8.3 fTBI  Cy  Flu   N 0 0 A & W
955 SAA 38/F 43/F 8 fTBI  Cy  Flu   N 0 0 A & W
971 SAA 10/F 40/F 8 fTBI  Cy  Flu   N 0 0 A & W
954 FA 8/M 41/F 8.3 Cy  Flu   N I 0 A & W
MNC indicates mononuclear cells; Bu, busulfan; fTBI, fractionated total body irradiation; Flu, ﬂudarabine; FA, Fanconi anemia; A & W, alive and well.
Table 2. Inborn Errors of Metabolism: Patient and Donor Characteristics
Patient No. Diagnosis
Recipient
Age (y)/Sex
Donor
Age (y)/Sex
Cell Dose
(MNC108/kg) Conditioning
CMV Serology
G-CSF
5g/kg/d
Acute
GVHD Grade
Chronic
GVHD Grade OutcomeDonor Recipient
393 ALD 6/M 43/F 2.9 Bu  Cy   N 0 0 A & W
412 MLD 1/M 35/M 7.7 Bu  Cy   N II 0 A & W
422 MPS III 4/M 37/F 2.1 Bu  Cy   N II 0 Dead, pneumonia
525 FHLH 1/F 25/F 18.1 Bu  Cy  VP-16   Y I NE Dead, VOD, CMV
pneumonia
644 FHLH 1/M 42/M 5.7 Bu  Cy  VP-16   Y II 0 A & W
707 ALD 39/M 28/M 1.6 fTBI  Cy   Y I Mild A & W
750 FHLH <1/M 47/M 59.3* Bu  Cy  VP-16   Y II 0 A & W
784 MPS I 1.5/M 28/F 25.8 Bu  Cy   Y II 0 A & W
793 SCID 0.5/M 41/M 43 Bu  Cy   Y 0 0 A & W
848 MLD 18/F 31/M 1.46 Bu  Cy   Y 0 Mild A & W
855 MPS I 1/M 30/M 18.5 Bu  Cy   Y 0 0 A & W
897 MPS I 1/F 32/M 2.9 Bu  Cy   N I 0 A & W
931 FHLH 0.5/M 23/M 5.7 Bu  Cy  VP-16   N I Mild A & W
ALD indicates adrenoleukodystrophy; MLD, metachromatic leukodystrophy; MPS I, mucopolysaccharoidosis type 1 (Hurler disease), MPS III, Sanﬁlippo syndrome; FHLH, familial hemophagocytic
lymphohistiocytosis, SCID, severe combined immune deﬁciency; Bu, busulfan; VP-16, etoposide; fTBI, fractionated total body irradiation; VOD, veno-occlusive disease; A & W, alive and well; NE,
not evaluable.
*Patients who received a PBSC graft.
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8aplan-Meier method, taking censored data into ac-
ount, and were compared by using the log-rank test.
he Mann-Whitney U test was used for comparing
he day of engraftment.
ESULTS
ngraftment and Transfusions
Two patients (patients 422 and 707) rejected their
rafts. Patient 422, a patient with Sanﬁlippo A disease,
ied of pneumonia on day 175 after the transplanta-
ion. Patient 707 underwent a second transplantation
ith the same donor after conditioning with ﬂudara-
ine 30 mg/m2/d for 5 days and ATG at a total dose
f 3.8 mg/kg. This patient is alive and a full donor
himera 2 years after the retransplantation.
An ANC0.5 109/L was reached at a median of
9 days (range, 11-26 days) for the bone marrow
atients. In those receiving peripheral blood stem cells
PBSC), the median was 11 days (range, 10-27 days;
 .18). Patients given bone marrow reached a plate-
et level of 30  109/L at a median of 24 days (range,
2-150 days), whereas those given PBSCs had platelet
ngraftment at a median of 12 days (range, 8-41 days;
ot signiﬁcant; P  .3). Patients receiving G-CSF had
faster neutrophil engraftment: median, day 16
range, 10-27 days) versus day 19 (range, 14-35 days;
 .07).
The SAA patients received a median of 6 erythro-
yte concentrates (range, 2-12) in the ﬁrst 2 months
nd a median of 13 platelet transfusions (range, 3-21).
n the patients with IEM, the corresponding ﬁgures
ere 4.5 (range, 0-17) and 7 (range, 0-29; not signif-
cant).
nfections
Fifteen patients had bacteremia: 9 caused by co-
gulase-negative staphylococci, 3 by -streptococci,
nd 1 by Staphylococcus aureus. Another patient (patient
48) had bacteremia caused by Escherichia coli and 1
patient 887) by Citrobacter species. Cytomegalovirus
CMV) DNA was detected by polymerase chain reac-
ion in the blood of 8 patients (42%). One patient with
LH (patient 525) died of interstitial CMV pneumo-
ia and veno-occlusive liver disease on day 36 after
ransplantation. Three patients, 2 with reactivated
erpes simplex virus (patients 249 and 525) and 1 with
aricella-zoster virus (patient 731), recuperated well
fter treatment. Patient 520, with SAA, developed
cute respiratory distress syndrome (ARDS) and died
f adenovirus type II positive pneumonia on day 241
fter transplantation.
raft-versus-Host Disease
Nine patients had no signs of acute GVHD. Ten
atients had acute GVHD grade I, and 6 had acute s
80VHD grade II. Of the 4 patients who received my-
ophenolate mofetil plus CsA as prophylaxis, 1 devel-
ped grade I acute GVHD, and another developed a
ild form of chronic GVHD. The cumulative inci-
ence of acute grade II to IV GVHD was 24% in all
atients. Six of 13 children (18 years) developed
rades II to IV acute GVHD, but none of the adults
id (P  .05). Of those who developed acute grade II
VHD, 4 of the 6 had received G-CSF [23]. None of
he children, but 4 of the 6 adults, developed chronic
VHD (P  .02). The cumulative incidence was
1%; 24 of 25 patients were valuable for chronic
VHD. None of the patients who were given a PBSC
raft developed chronic GVHD. No patient died of
VHD (Tables 1 and 2).
urvival Rates
The overall 5-year survival rate was 84% (Fig-
re 1). The median follow-up of the surviving patients
as 3.6 years (range, 0.8-14.5 years). The probability
f survival was 83% in the SAA group and 85% in the
EM group. Two of the SAA patients died, 1 of Evans
yndrome (patient 441) and 1 of ARDS (patient 520;
able 1). Among the patients with IEM, there were
deaths: 1 patient with Sanﬁlippo syndrome (patient
22) who died of pneumonia and 1 patient with HLH
patient 525) who died of CMV pneumonia and veno-
cclusive disease. The remaining 21 patients are alive
nd well (Tables 1 and 2).
ISCUSSION
Our aim was to evaluate the outcome of HSCT in
atients with nonmalignant disease who had received
losely matched unrelated grafts at Huddinge Univer-
igure 1.Cumulative probability of survival after HSCT in patients
ith nonmalignant disorders—IEM (inborn errors of metabolism)
nd SAA (severe aplastic anaemia)—by using matched unrelated
onors.ity Hospital, of whom 12 had SAA and 13 had IEM.
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MUD-HSCT for Nonmalignant Disorders
Bwo of the 25 patients rejected the transplant. It is
oteworthy that no rejection occurred in the SAA
atients, although this group is prone to rejection
2,10]. The patients in the SAA group were presum-
bly a high-risk group, having experienced treatment
ailure with immunotherapy and having received nu-
erous transfusions before transplantation [9]. To
void rejection in these patients, no patient had been
iven the standard regimen with Cy alone. In 1 pa-
ient, Cy was combined with TLI, and in another
atient, Cy was combined with busulfan. However, in
ll other patients, Cy was combined with TBI with or
ithout ﬂudarabine. Various regimens have thus been
sed, but we recommend ﬂudarabine, Cy, and frac-
ionated TBI because of its lower toxicity. The use of
TG during conditioning may also have prevented
ejection in these patients [18].
The engraftment of neutrophils and platelets was
aster in PBSC patients than in those receiving bone
arrow, although the difference was not statistically
igniﬁcant. In larger studies, PBSC grafts are associ-
ted with faster engraftments of neutrophils and plate-
ets, probably because of the larger number of CD34
ells in these grafts [15]. The times to engraftment
ere similar to those reported in comparable patients
ith leukemia [16].
The incidence of infections in this study also re-
embled that in patients with malignant diseases—
8% with bacterial septicemia and 42% with reacti-
ation of CMV [24]. The latter occurred mainly in the
AA patients, of whom 6 of 7 were seropositive before
he transplantation. One death due to CMV occurred
n a patient with HLH, and 2 other deaths were
aused by infections: 1 from ARDS (adenovirus
ype II) and 1 from pneumonia.
ATG was primarily given to reduce the risk of
raft rejection, but this also probably played a role in
he low incidence of acute GVHD. None of the pa-
ients developed GVHD grade III or IV. We have
reviously shown, using unrelated donors, that ATG
educes the risk of acute GVHD after HSCT [25].
ore children than adults developed moderate acute
VHD (P  .05). Despite the correlation between
cute and chronic GVHD [26,27], none of them de-
eloped chronic GVHD, whereas 4 of 6 adults did.
his would suggest that age may be more important
han acute GVHD as a risk factor for chronic GVHD
n this small patient population. The prolonged im-
unosuppression—up to 2 years—may also be a rea-
on for the low incidence of chronic GVHD. In this
tudy, only 5 patients received PBSC grafts. None
eveloped chronic GVHD. However, in larger stud-
es, there is a strong association between PBSC grafts,
ompared with bone marrow grafts, and chronic
VHD [28]. Chronic GVHD is not desirable in pa-
ients with nonmalignant diseases, and, therefore,
one marrow grafts may be preferable. T
B & M TWe found an encouraging 5-year survival of 84%
mong these 25 patients. This indicates that an
LA-A, -B and -DR1 MUD is an acceptable alter-
ative for patients with nonmalignant disorders who
ack a matched sibling donor. The circumstance that
ll cases but 1 were genomically matched for the major
LA antigens is probably of major importance for the
utcome [7]. Although only 12 SAA patients were
ncluded, a 5-year survival of 83% is promising in
omparison with other (albeit larger) studies [9,10,29].
ur data suggest that a well-matched unrelated donor
ould be considered earlier in the course of the disease
n such patients, because prolonged immunosuppres-
ive treatment increases the risk for immunization,
ubsequent rejection, and infections. In the patients
ith IEM, the 5-year survival was 85%, which is also
ncouraging, although it is lower than with HLA-
dentical sibling donors [17]. However, in these pa-
ients, there is no other curative treatment. Therefore,
SCT is considered as soon as the diagnosis is made
nd a suitable donor can be found [3,4,12]. It should
e pointed out that although the 5-year survival is
avorable, this study does not question previous rec-
mmendations concerning the optimal time of trans-
lantation.
In those with life-threatening nonmalignant dis-
rders who do not have an HLA-identical sibling, an
SCT with a well-matched unrelated donor seems to
e the treatment of choice. If such a donor is not
vailable, then an alternative could be a cord blood
ransplant or a haploidentical related donor transplant
30-32]. However, with a cord blood transplant, en-
raftment is delayed, and the risk of rejection may be
igher, especially if the cell dose is low. With hap-
oidentical related donors, T-cell depletion is neces-
ary to minimize the risk of GVHD. With this ap-
roach, rejection and immunoincompetence may be a
roblem, with a subsequent increased risk of post-
ransplantation infections.
In conclusion, our study suggests that patients
ith nonmalignant disorders can successfully undergo
ransplantation with an unrelated graft if the donor is
losely HLA-A, -B, and -DR1 matched with high-
esolution techniques and if ATG is included in the
onditioning regimen. Under these circumstances,
utcome is similar to that in HLA-identical sibling
ransplantations.
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